Bristol Myers Squibb Company
NEWS
In an analysis of BMS’ recent clinical history, Industry analysts at Trefis noted that two oncology drugs will be key revenue drivers for the company.
Bristol-Myers Squibb has its eyes set on carving out a strong position in the lucrative Chinese lung cancer market.
The company announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral.
While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
BMS is pushing forward with its internal IDO1 program and showing off early-stage data from its Phase I/IIa combination trial of Opdivo plus BMS-986205, an IDO1 inhibitor.
Bristol-Myers is initiating a Phase III clinical trial of BMS-986205 with nivolumab in patients with advanced melanoma.
Here’s a closer look at six drugs facing FDA decisions in November.
JOBS
IN THE PRESS